Improved glycemic control with weight loss and a low risk of hypoglycemia with insulin detemir: Insights from the Italian cohort of the PREDICTIVE study after 6-month observation in type 2 diabetic subjects

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 16, 2011, Pages 2449-2455

  Perriello, Gabriele ^a   Caputo, Salvatore ^b   De Pergola, Giovanni ^c   Di Carlo, Alberto ^d   Grassi, Giorgio ^e   Lapolla, Annunziata ^f   Pata, Pietro ^g   Solerte, Sebastiano Bruno ^h   Zaccardi, Francesco ^b  

^a UNIVERSITY OF PERUGIA   (Italy)

^b FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^c UNIVERSITY OF BARI   (Italy)

^d USL 2   (Italy)

^e Endocrinologia Diabetologia e Metabolismo   (Italy)

^f UNIVERSITY OF PADOVA   (Italy)

^g AOR Papardo Piemonte di Messina   (Italy)

^h UNIVERSITY OF PAVIA   (Italy)

Author keywords

insulin detemir; observational study of insulin detemir; predictive study; safety and efficacy of insulin detemir

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN DETEMIR; ORAL ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; BLOOD GLUCOSE MONITORING; BODY WEIGHT; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; DIABETIC PATIENT; DRUG FEVER; DRUG SAFETY; DYSPNEA; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART FAILURE; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; ITALY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PREDICTION; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; TREATMENT DURATION; WEIGHT REDUCTION;

ADULT; AGED; BLOOD GLUCOSE SELF-MONITORING; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN, LONG-ACTING; ITALY; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 80054068546     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2011.626766     Document Type: Article

References (21)

1. Volume by International Diabetes Federation. Available from: http://www.diabetesatlas.org [Last accessed 1 December 2010]
2. Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58:773-95
3. Swinnen SG, Hoekstra JB, DeVries JH. Insulin therapy for type 2 diabetes [review]. Diabetes Care 2009;12(Suppl 2):S253-9
4. Plank J, Bodenlenz M, Sinner F, et al. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care 2005;28:1107-12 (Pubitemid 40616620)
5. Havelund S, Plum A, Ribel U, et al. The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm Res 2004;21:1498-504 (Pubitemid 39149667)
6. Heise T, Nosek L, Ronn BB, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004;53:1614-20 (Pubitemid 38697678)
7. Hermansen K, Fontaine P, Kukolja K, et al. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia 2004;47:622-9 (Pubitemid 38658363)
8. Home P, Bartley P, Russell-Jones D, et al. Study to Evaluate the Administration of Detemir Insulin Efficacy, Safety and Suitability (STEADINESS) Study Group. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial. Diabetes Care 2004;27:1081-7 (Pubitemid 38579770)
9. Rosenstock J, Davies M, Home PD, et al. Insulin detemir added to oral anti-diabetic drugs in type 2 diabetes provides glycemic control comparable to insulin glargine with less weight gain. Diabetes 2006;55:A132
10. Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med 2000;342:1878-86 (Pubitemid 30419053)
11. Ligthelm RJ, Borz V, Gumprecht J, et al. Importance of observational studies in clinical practice. Clin Ther 2007;29:1284-92 (Pubitemid 351181208)
12. Marre M, Pinget M, Gin H, et al. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain: 52-week data from the PREDICTIVE study in a cohort of French patients with type 1 or type 2 diabetes. Diabetes Metab 2009;35:469-75
13. Preumont V, Buysschaert M, De Beukelaer S, et al. Insulin detemir in routine clinical practice: a 26-week follow-up in type 1 diabetic patients from the Belgian PREDICTIVE Cohort. Acta Clin Belg 2009;64:49-55
14. Kurtoglu S, Atabek ME, Dizdarer C, et al. PREDICTIVE Turkey Study Group. Insulin detemir improves glycemic control and reduces hypoglycemia in children with type 1 diabetes: findings from the Turkish cohort of the PREDICTIVE observational study. Pediatr Diabetes 2009;10:401-7
15. Selam JL, Koenen C, Weng W, et al. Improving glycemic control with insulin detemir using the 303 Algorithm in insulin naive patients with type 2 diabetes: a subgroup analysis of the US PREDICTIVE 303 study. Curr Med Res Opin 2008;24:11-20 (Pubitemid 351160234)
16. von Elm E, Altman DG, Egger M, et al. STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies [review]. PLoS Med 2007;4:e296
17. Luddeke HJ, Sreenan S, Aczel S, et al. PREDICTIVE - a global, prospective, observational study to evaluate insulin detemir treatment in type 1 and 2 diabetes: baseline characteristics and predictors of hypoglycaemia from the European cohort. Diabetes Obes Metab 2007;9:428-34 (Pubitemid 46502063)
18. Dornhorst A, Luddeke H-J, Sreenan S, et al. on behalf of the PREDICTIVE Study Group. Safety and efficacy of insulin detemir in clinical practice: 14-week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVETM European cohort. Int J Clin Pract 2007;61:523-8
19. Gimeno-Orna JA, Castro-Alonso FJ, Boned-Juliani B, et al. Fasting plasma glucose variability as a risk factor of retinopathy in type 2 diabetic patients. J Diabetes Complications 2003;17:78-81 (Pubitemid 36279504)
20. Zoppini G, Verlato G, Targher G, et al. Is fasting glucose variability a risk factor for retinopathy in people with type 2 diabetes? Nutr Metab Cardiovasc Dis 2008;19:334-9
21. Vandenbroucke JP. What is the best evidence for determining harms of medical treatment? CMAJ 2006;174:645-6 (Pubitemid 43341875)